Even in the West of Scotland coronary heart disease (CHD) is uncommon in premenopausal women.' The relation between surgically induced early menopause and an increased risk of cardiovascular disease is undisputed but the increased risk of cardiovascular disease seen with early natural menopause may be explained by its association with cigarette smoking. Does the postmenopausal state increase cardiovascular risk? Data from the United States did not show an increase in "the rate of increase" of death from CHD around or after the menopause.2 Likewise a large study in American nurses3 did not show any clear increase in cardiovascular mortality and morbidity at the time of the menopause. Poor sensitivity in determining the time of the menopause may make it difficult to establish a relation between the menopause and an increased risk of cardiovascular disease in large population studies such as these.
If HRT."12-4 All three showed significantly less CHD in women who were taking replacement oestrogens, with a risk reduction for severe disease of around 60% even after adjustment for other CHD risk markers. The greatest benefit on subsequent survival was seen in those in whom CHD had already developed.
These beneficial cardiovascular effects were shown for unopposed oestrogen use. There is justifiable concern about endometrial and breast cancer developing in association with the use of HRT. Endometrial cancer can be prevented by the concomitant use of progesterone, but cyclical bleeding is a major disincentive to taking HRT. The beneficial effects of HRT cannot be fully explained through its actions on plasma lipids. Newer preparations of combined oestrogen and progesterone reduce not only LDL cholesterol but also HDL cholesterol, at least in the short term.'5 There is concern about the possible adverse effects of progesterone on the lipid profile and until recently the long-term effects of combined oestrogen and progesterone on CHD risk were unclear. It is encouraging that a recent study showed that the combined preparation was also associated with a significantly reduced risk of CHD. So from a cardiological viewpoint it seems reasonable to recommend the combined preparation in postmenopausal women'6 who have not had a hysterectomy. None the less, the potential gynaecological side effects may make many cardiologists reluctant to initiate therapy. There is obvious scope for close collaboration with gynaecologists.
The question whether the incidence of breast cancer is increased by HRT is unresolved. In an excellent review Speroff considered all the health issues and favoured HRT but he also concluded that the evidence for an increase in incidence and mortality from breast cancer is equivocal.'7 Any possible excess relative risk is clearly outweighed, at least in mortality terms, by its beneficial effect on CHD. But many women may not be prepared to take HRT while the slightest possibility of an increase in risk of breast cancer remains.
Unbridled enthusiasm for HRT must be tempered by the fact that most studies were observational and thus subject to selection bias. The participants were predominantly white, relatively affluent, and complied with treatment.'8 Because the health benefits of social class and education are not fully understood it is not possible to adjust fully for them. Compliance with therapy is important and even in patients taking placebo, compliance correlated positively with reduced risk of developing CHD in intervention trials.'9 Thus randomised clinical trials are required to determine whether HRT helps to prevent the development of CHD in postmenopausal women. Such studies are planned but until the results are known we can only remark that if a therapy that seemed to reduce CHD incidence by 50% were available to men they would be encouraged to take it. 
